Key Points
- CFO Ivan Hyep sold 9,200 shares of Bicara Therapeutics on March 23 at an average price of $18.52 for $170,384, reducing his stake by 5.95% to 145,355 shares (SEC filing disclosed).
- Pattern of insider selling: Hyep sold a total of 27,600 shares across January–March (including March 3 and 4), generating roughly $505,589 in proceeds, indicating sustained insider exits over the period.
- Market and analyst context: BCAX traded around $18.68 (up 2.9%), has a ~$1.02 billion market cap, and carries a consensus analyst rating of “Moderate Buy” with a $30.78 average target price.
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $18.52, for a total transaction of $170,384.00. Following the completion of the sale, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,691,974.60. This represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Ivan Hyep also recently made the following trade(s):
- On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.25, for a total transaction of $54,074.75.
- On Tuesday, March 3rd, Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.22, for a total transaction of $246,972.10.
- On Thursday, January 22nd, Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.15, for a total value of $34,158.30.
Bicara Therapeutics Trading Up 2.9%
Shares of BCAX stock opened at $18.68 on Thursday. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $20.25. The stock's 50-day moving average price is $17.03 and its 200-day moving average price is $16.44. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -8.34 and a beta of -0.78.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC purchased a new stake in Bicara Therapeutics during the first quarter valued at approximately $248,000. Woodline Partners LP boosted its holdings in shares of Bicara Therapeutics by 26.5% in the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company's stock worth $4,543,000 after purchasing an additional 72,998 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company's stock worth $6,248,000 after purchasing an additional 180,833 shares during the period. Police & Firemen s Retirement System of New Jersey increased its position in shares of Bicara Therapeutics by 119.6% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company's stock valued at $75,000 after purchasing an additional 4,417 shares during the last quarter. Finally, Intech Investment Management LLC raised its holdings in Bicara Therapeutics by 65.3% during the 2nd quarter. Intech Investment Management LLC now owns 27,673 shares of the company's stock valued at $257,000 after buying an additional 10,927 shares during the period.
Analyst Ratings Changes
Several research firms have weighed in on BCAX. Weiss Ratings restated a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Mizuho upgraded Bicara Therapeutics to a "hold" rating in a research report on Thursday, December 18th. UBS Group reissued a "buy" rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Citizens Jmp began coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They issued a "market perform" rating and a $31.00 price target on the stock. Finally, Wedbush reaffirmed an "outperform" rating and set a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Bicara Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.78.
Get Our Latest Report on Bicara Therapeutics
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
